BACKGROUND: It is still unknown when drug-eluting stent in-stent restenosis happens, which type of drug-eluting stents should be implanted during percutaneous coronary intervention.
OBJECTIVE: To evaluate the efficacy and safety of the same versus different types of drug-eluting stents in treating coronary artery disease patients suffering from in-stent restenosis after first percutaneous coronary intervention using drug-eluting stents.
METHODS: PubMed, EMBASE, Google Scholar Research, Cochrane Library and Chinese BioMedical Literature Database on disc were searched for clinical trials about the same and different types of
drug-eluting stents in treating coronary artery disease patients suffering from in-stent restenosis after first percutaneous coronary intervention using drug-eluting stents. Then, a meta-analysis was performed.
RESULTS AND CONCLUSION: Six articles were enrolled in the meta-analysis, including 983 cases of in-stent restenosis who received sirolimus-eluting stents or paclitaxel-eluting stents re-implantation following first drug-eluting stent implantation. There were no significant differences between the same and different type of re-implanted drug-eluting stents in all-cause mortality (P=0.31, I2=14%, odd ratio (OR)=0.92, 95% confidence index (CI) [0.40,2.08]), secondary myocardial infarction (P=0.64, I²=0, OR=2.68, 95% CI[1.00,7.24]), the incidence of in-stent thrombosis (P=0.82, I²=0, OR=2.02, 95% CI[0.37,11.08]), and target lesion revascularization (P=0.63, I²=0, OR=1.15, 95% CI[0.75,1.76]). Based on the obtained statistical results, there was no difference between the efficacy and safety of the same and different types of drug-eluting stents for treatment of in-stent restenosis following the first percutaneous coronary intervention using drug-eluting stents.